On October 17, 2025, BiomX Inc. reported receiving additional, focused questions from the FDA regarding a nebulizer for its BX004 drug candidate for Cystic Fibrosis, with no concerns about the drug itself; enrollment for the European study continues ahead of schedule, and topline results are expected in Q1 2026.